Cargando…

Palmitoylethanolamide (PEA) as a Potential Therapeutic Agent in Alzheimer’s Disease

N-Palmitoylethanolamide (PEA) is a non-endocannabinoid lipid mediator belonging to the class of the N-acylethanolamine phospolipids and was firstly isolated from soy lecithin, egg yolk, and peanut meal. Either preclinical or clinical studies indicate that PEA is potentially useful in a wide range of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beggiato, Sarah, Tomasini, Maria Cristina, Ferraro, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667638/ https://www.ncbi.nlm.nih.gov/pubmed/31396087 http://dx.doi.org/10.3389/fphar.2019.00821

Ejemplares similares

Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer’s Disease
por: Beggiato, Sarah, et al.
Publicado: (2020)

Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer’s Disease
por: D’Antongiovanni, Vanessa, et al.
Publicado: (2021)

In Vitro Functional Characterization of GET73 as Possible Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5
por: Beggiato, Sarah, et al.
Publicado: (2018)

Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential
por: Nestmann, Earle R.
Publicado: (2016)

Evaluation of bumetanide as a potential therapeutic agent for Alzheimer’s disease
por: Boyarko, Ben, et al.
Publicado: (2023)

Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation
por: Roncati, Luca, et al.
Publicado: (2021)

Innovative Nanoparticles Enhance N-Palmitoylethanolamide Intraocular Delivery
por: Puglia, Carmelo, et al.
Publicado: (2018)

Engineered Lactobacillus paracasei Producing Palmitoylethanolamide (PEA) Prevents Colitis in Mice
por: Esposito, Giuseppe, et al.
Publicado: (2021)

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse
por: Roviezzo, Fiorentina, et al.
Publicado: (2017)

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients
por: Noce, Annalisa, et al.
Publicado: (2021)

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?
por: Angelucci, Francesco, et al.
Publicado: (2019)

Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease
por: Bellanti, Francesco, et al.
Publicado: (2022)

The Nutraceutical N-Palmitoylethanolamide (PEA) Reveals Widespread Molecular Effects Unmasking New Therapeutic Targets in Murine Varicocele
por: Antonuccio, Pietro, et al.
Publicado: (2021)

Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study
por: Albanese, Maria, et al.
Publicado: (2022)

Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect
por: Petrosino, Stefania, et al.
Publicado: (2018)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury
por: Crupi, Rosalia, et al.
Publicado: (2016)

Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease
por: Behl, Tapan, et al.
Publicado: (2022)

A Palmitoylethanolamide Producing Lactobacillus paracasei Improves Clostridium difficile Toxin A-Induced Colitis
por: Esposito, Giuseppe, et al.
Publicado: (2021)

Adenosine and Kynurenic Acid Interactions: Possible Relevance for Schizophrenia Treatment?
por: Beggiato, Sarah, et al.
Publicado: (2021)

Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
por: Scuteri, Damiana, et al.
Publicado: (2022)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

Palmitoylethanolamide (PEA) Inhibits SARS-CoV-2 Entry by Interacting with S Protein and ACE-2 Receptor
por: Fonnesu, Rossella, et al.
Publicado: (2022)

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
por: Valenza, Marta, et al.
Publicado: (2022)

Palmitoylethanolamide Reduces Neuropsychiatric Behaviors by Restoring Cortical Electrophysiological Activity in a Mouse Model of Mild Traumatic Brain Injury
por: Guida, Francesca, et al.
Publicado: (2017)

Therapeutic potential of mGluR5 targeting in Alzheimer's disease
por: Kumar, Anil, et al.
Publicado: (2015)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes
por: Piccialli, Ilaria, et al.
Publicado: (2022)

Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes
por: Pavan, Barbara, et al.
Publicado: (2018)

A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol
por: Huschtscha, Zoya, et al.
Publicado: (2023)

Efficacy of a Combination of N-Palmitoylethanolamide, Beta-Caryophyllene, Carnosic Acid, and Myrrh Extract on Chronic Neuropathic Pain: A Preclinical Study
por: Fotio, Yannick, et al.
Publicado: (2019)

Co-Ultramicronized Palmitoylethanolamide/Luteolin-Induced Oligodendrocyte Precursor Cell Differentiation is Associated With Tyro3 Receptor Upregulation
por: Facci, Laura, et al.
Publicado: (2021)

Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects
por: Scuderi, Caterina, et al.
Publicado: (2018)

Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer’s disease
por: Makhaeva, Galina F., et al.
Publicado: (2023)

Icariin and Its Metabolites as Potential Protective Phytochemicals Against Alzheimer’s Disease
por: Angeloni, Cristina, et al.
Publicado: (2019)

Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis
por: Di Paola, Rosanna, et al.
Publicado: (2016)

Cellular and animal models for high-throughput screening of therapeutic agents for the treatment of the diseases of the elderly in general and Alzheimer’s disease in particular(†)
por: Holtzman, Jordan L.
Publicado: (2013)

Orofacial Pain Management: An Overview of the Potential Benefits of Palmitoylethanolamide and Other Natural Agents
por: Santonocito, Simona, et al.
Publicado: (2023)

Micronized Palmitoylethanolamide Ameliorates Methionine- and Choline-Deficient Diet–Induced Nonalcoholic Steatohepatitis via Inhibiting Inflammation and Restoring Autophagy
por: Hu, Jiaji, et al.
Publicado: (2021)

Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
por: Facchinetti, Roberta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o05j8k1gmj4lbo6pm4emtrmk85